The effect of polymorphisms (174G> C and 572C> G) on the Interleukin-6 gene in coronary artery disease: a systematic review and meta-analysis

Nader Salari1, Kamran Mansouri2, Amin Hosseinian-Far3, Hooman Ghasemi4, Masoud Mohammadi5, Rostam Jalali5 and Aliakbar Vaisi-Raygani5

Abstract

Background: Coronary Artery Disease (CAD) is caused by the blockage of the coronary arteries. It is argued that there is an association between the Interleukin-6 gene and the occurrence of atherosclerosis, coronary artery disease. Due to the short half-life and high variability of Interleukin-6 (IL-6), limited studies have been performed on the association of serum levels of interleukin-6 with coronary artery disease. The aim of this study is to investigate the relationship between IL-6 gene polymorphisms and coronary artery disease.

Methods: This study was conducted as a meta-analysis of selected articles with no lower time limit and up to March 2020. Articles related to the subject were obtained by searching several data sources, such as the SID, IranDoc, Scopus, Embase, Web of Science (ISI), PubMed, Science Direct, and Google Scholar databases. The heterogeneity of the studies was assessed using the I² index in the Comprehensive Meta-Analysis software.

Results: The GG genotype of the IL-6174 G> C polymorphism with a 0.8 odds ratio tended to reduce the risk of CAD by 20%. The odds ratio of CAD in CG and GG genotypes were found to be 1.16 and 1.48 times respectively, indicating the increasing effect of these two genotypes. In the IL-6-572 C>G polymorphism, CG and GG genotypes increased the risk of CAD by 1.21 and 1.27 times respectively, and the CC genotype tended to reduce the risk of CAD by 15%, considering the odds ratio of 0.85.

Conclusion: This study showed a relationship between IL-6174G> C and Interleukin-6 (IL-6) 572 C>G genes and coronary artery disease. Moreover, the protective effects of GG genotype in IL-6 gene 174 G> C and CC genotype in IL-6 gene 572 C>G gene were reported. The study also confirmed that the CG and CC genotypes of the G>C IL-6174 gene have an increasing effect on coronary artery disease. Moreover, CG and GG genotypes in the IL-6 gene 572 C>G increased the risk of developing CAD. It should be noted that the increased risk of developing CAD was limited to meta-analytic studies in reported literatures.

Keywords: Coronary artery disease, Polymorphism, Cardiovascular disease, IL-6174 G> C, IL-6 -572C> G, Atherosclerosis
Background

Cardiovascular diseases are known to be a leading disorder that embrace a wide range of specific diseases such as vascular disorders, Myocardial Infarction (MI), and congenital heart disease. In fact, such diseases involve disorders of the cardiovascular and blood circulation systems. Cardiovascular diseases are known to be a top cause of human mortality worldwide. Studies have shown that cardiovascular disorders are more likely to cause death in the general population than other diseases such as infectious diseases, maternal and infant diseases, nutritional disorders, and cancers [1–4]. The mortality rate from cardiovascular diseases is reported to be 45% [5]. The constant accumulation of fat, immune cells, and fibrous tissues in the lining of the arteries can block the arteries. This can lead to decreased alertness, decreased blood flow, and eventually a cardiovascular disease [6].

Atherosclerosis is a cardiovascular disorder and a chronic inflammatory response by the body that has stable and unstable periods. This disorder occurs in the large and medium arteries. The cause of this disease is fat and cholesterol accumulation in the wall of the arteries [7, 8]. Atherosclerotic lesions are caused by asymmetric thickening of the inner layer of the arteries [9]. Acute Coronary artery Syndrome (ACS), Coronary Artery Disease (CAD), Myocardial Infarction (MI), stable and unstable angina, stroke, transient ischemic attack and peripheral arterial disease are known as atherosclerotic subunits [10].

Coronary Artery Disease (CAD) is caused by a blockage of the coronary arteries. The disease can cause myocardial ischemia and eventually necrosis of the heart. CAD is considered the leading cause of death in different populations. The formation of atherosclerotic plaques is a major factor in the advancement of CAD. Although the mechanism is not unknown and the research of that is limited, the role of inflammation in the occurrence of atherosclerotic plaques cannot be ignored [11]. Angina and myocardial infarction can be considered as some of the clinical indicators of this disease [11–13]. Several types of immune cells, including macrophages, and T and B lymphocytes also accumulate in the arterial walls and are involved in the development of atherosclerotic disorders through cytokines and other mediators [14].

Cytokines are small proteins that, in addition to the immune system, have a wide range of physiological roles. These proteins are produced by different types of cells. Functional pleiotropy is one of the characteristics of this group of materials and makes cytokines able to play a regulatory role in cell differentiation and proliferation activities according to cell type and status. Different types of cytokines include interleukins, interferon, and growth factors [15, 16].

There are several factors that contribute to coronary artery disease. However, these factors vary from one person to another. Genetics is considered to be one of the factors influencing the development of CAD. Some studies have reported 50 risk points in the human genome that can influence CAD development [17]. Extensive genomic studies demonstrate that genetic factors increase the chances of developing CAD by 1.1 to 1.3 times [18]. It has also been shown that hereditary factors account for 30–60% of interpersonal differences in CAD [19]. The severity of the genetic effect depends on factors such as the age of the person at the onset point and also the type of disease [4].

The Interleukin-6 (IL-6) encoding gene is located on the 7P21 chromosome and contains 6 exons. Most studies have focused on the Interleukin-6 (IL-6) gene promoter region. This is because many single-nucleotide polymorphisms, such as IL-6-1744 G / C polymorphisms, IL-6 -572 C / G, and IL-6 -598, are located in this region [20]. Sie et al. (2006) argue that IL-6174 polymorphism is effective in transcribing the Interleukin-6 (IL-6) gene and, consequently, in the plasma level of IL-6 [21]. On the other hand, it is argued that there has been an association between the IL-6572 gene and the occurrence of atherosclerosis, coronary artery disease, and MI [22].

IL-6 is the main stimulus for the acute phase response and stimulates liver synthesis and enhances the C-reactive protein (CRP) [23]. This protein is a precursor to vascular atheromatobiotic disease and is involved in the pathogenesis of atherosclerosis. Elevated plasma levels of IL-6 and CRP increase the risk of death in the elderly. On the other hand, serum IL-6 levels are high in people with unstable angina, which is a symptom of coronary artery disease [23–25].

IL-6 is known as a cytotoxic polytropic. This protein is involved in activities such as activating macrophages, stimulating B and T cells, and thymocytes in the process of differentiation, regulating restorative activities, and replicating and inducing the activities of the immune system, and the cardiovascular and nervous systems. Interleukin-6 family of proteins include Leukemia Inhibitory Factor (LIF), cardiothropin-1 (CT-1), IL-6, and IL-11. Interleukin-6 is expressed by tissue immune cells. Cardiovascular cells such as endothelial cells, smooth muscle cells, and ischemic myocytes also play a part in the expression of IL-6 proteins [15, 16, 23, 26] (Fig. 1).

IL-6 connects to its membrane receptor; This receptor consists of two sub-units IL-6 and gp130. Once IL-6 is connected to IL-6R, it activates soluble IL-6R. The IL-6, SIL-6R complex as a potent agonist activates Glycoprotein 130 (a signal transmission component), and this process enhances the IL-6 mechanism. IL-6 plays an important role as a mediator of inflammation.
Due to the short half-life and high variability of Interleukin-6 (IL-6), limited studies have been performed on the association of serum levels of interleukin-6 with coronary artery disease [27]. Moreover, the interactions between cardiovascular risk factors, inflammatory mechanism and atheromatosis are complex [25]. Given the importance of recognizing people prone to heart disease, the risks associated with the disease and since the disease has a high mortality rate, Knowing the factors that affect its occurrence can be effective in macro-planning to control and prevent the occurrence of the disease and its complications in different populations. In this study, the relationship between IL-6 gene polymorphism and coronary artery disease is examined.

**Methods**

**Search method**

This study was performed to determine the relationship between cytokine gene polymorphism and cardiovascular disorders by systematic review and meta-analysis. To collect data in this study, Iranian and international databases of Embase, Scopus, Web of Science, PubMed, Science Direct, ProQuest, Google Scholar, SID, and Irandoc were searched. Search process in the above-mentioned databases were conducted using the keywords: (“Interleukin gene” OR “Interleukin-6 (IL-6) gene” OR “IL-6 polymorphism” OR “IL-174G / C OR 572C / G OR 597G / A OR IL-6R OR RS1800795 OR RS1800796 OR RS1800797 OR “cytokine gene”) AND (“cardiovascular diseases” OR CVD OR CHD OR CAD OR MI OR atherosclerosis OR “heart failure” OR “heart diseases” myocardy “OR” coronary art infarction “OR” angina pectoris “OR” ischemic heart “)” . These keywords and their possible combination were searched in international databases, and for Persian databases the search was done using the Persian equivalent of the keywords expressed. Moreover, searches in Google Scholar were conducted separately both in English and in Persian, in order to identify gray literature. Assessment of relevant webpages, as well as analysing the references within collected sources were also conducted.

**Selection criteria, and article assessment**

After the search process, all the articles were collected in the EndNote software, and the duplicate articles were deleted. Criteria for entering articles into the study were: 1- case control studies and 2- cohort research, and 3- studies that link the genes expressing cytokines and cardiovascular disorders; Criteria for excluding the studies were: 1- cross-sectional studies 2- case reports 3- interventional studies 4-letters to editor 5- studies where their full text were not available, and 6- studies in which the study population had an underlying disease.

Then, a list of article titles and abstracts was put together, and after redacting the details of the articles, their full texts were provided to the reviewers. Each article was independently reviewed by two reviewers, and any disagreement was then reviewed by a third reviewer.
For assessing the quality of the collected articles, STROBE checklist was used. This checklist includes 22 criteria, 18 of which are used publicly for all observational studies and 4 items are used exclusively based on the type of study. The checklist criteria include study objectives, determining the appropriate sample size, type of study, sampling method, research community, data collection method, defining variables and how to review the samples, study data collection tools, study objectives, the statistical test used, and the results of the study. The maximum score for articles could be 31, and articles with a score below 14 were excluded from the study. The studies were then meta-analysed using the four step of (i.e. identification of articles, screening, review of admission criteria, and finally articles submitted to meta-analysis) PRISMA 2009 process (Fig. 2).

Statistical analysis
In this study, the heterogeneity of studies was examined using the $I^2$ test. In general, heterogeneity is classified into three categories, heterogeneity less than 25% (low heterogeneity), between 25 to 75% (medium heterogeneity) and above 75% (high heterogeneity). Data were meta-analysed using the Comprehensive Meta-analysis software (Biostat, Englewood, NJ, USA version 3).

Results
This study examined the relationship between IL-6572G> C and IL-6174 C> G gene polymorphism and coronary artery disease following a systematic review and meta-analysis. After searching various databases, 2619 articles were collected. 317 articles from EMBASE, 399 articles from ProQuest, 345 articles from PubMed, 149 articles from Science Direct, 313 articles from Scopus, 395 articles from Web of Science, 6 articles from SID, 10 articles from Irandoc, and 685 articles from Google Scholar. 786 duplicate articles were removed, and subsequently 1358 other articles were deleted after reviewing their title and abstract. 475 articles were then entered the secondary evaluation phase. By examining the full text of the articles in terms of relevance and quality, another 438 articles were excluded, and finally 37 articles entered the meta-analysis stage (Tables 1 and 2) [28–61].

Gene Interleukin-6 (IL-6) 174G> C
Investigation of heterogeneity and publication bias (GG, CG, CC genotypes)
The heterogeneity of the studies was investigated using $I^2$ test and based on this test, the heterogeneity in GG, CG and CC genotypes were calculated as $I^2 = 59.1\%$, $I^2 = 79.2\%$, and $I^2 = 70\%$ respectively. The
results demonstrate a high level of heterogeneity among articles, and therefore the random effects model was used to amalgamate the results from these studies. The publication bias was calculated using the Egger's test; the test did not find bias in any of the genotypes, since the results were not statistically significant ($P > 0.05$) (Table 3). One of the most important reasons for the high heterogeneity in the study is

| Rows | Name [references] | country | Year of publish | Mean age of case group (SD) | Mean age of control group (SD) | Case Group Population | Control group population |
|------|-------------------|---------|-----------------|-----------------------------|-------------------------------|----------------------|--------------------------|
| 1    | Amorim, Fernanda Gobbi [28] | Brazil | 2011 | 54.9 ± 1.1 | 54.9 ± 1.1 | 72 | 71 |
| 2    | Ansari, Wafa Munir [29] | Pakistan | 2017 | 42±3.80 | 42±3.80 | 340 | 310 |
| 3    | Babu, Baddela M. V. Srikanth [30] | India | 2012 | 53.56 ±11.72 | 52.62 ± 8.45 | 651 | 432 |
| 4    | Banerjee, Indranil [31] | India | 2009 | 56.3 ± 12.1 | 56.0 ± 9.5 | 210 | 232 |
| 5    | Basso, F [32]. | America | 2002 | 56±5 | 56±5 | 498 | 1108 |
| 6    | Bhanushali, A. A [33]. | India | 2013 | 48±11 | 50±11 | 100 | 150 |
| 7    | Chen, H [34]. | China | 2018 | 61.00 ± 10.49 | 60.37 ± 10.38 | 322 | 429 |
| 8    | Elsaid, A [35]. | Egypt | 2014 | 53.54 ± 9.1 | 45.3 ± 7.2 | 108 | 143 |
| 9    | Fan, W. H [36]. | China | 2011 | 52.1 ± 6.8 | 52.3 ± 8.8 | 84 | 130 |
| 10   | Fragoso, J. M [22]. | Mexico | 2010 | 58.88 ±11.7 | 56.03 ±4.13 | 284 | 247 |
| 11   | Galimudi, R. K [37]. | India | 2014 | 65±5 | 64±6 | 200 | 200 |
| 12   | Gao, Y. L [38]. | China | 2016 | 61.50±10.53 | 52.54±10.65 | 275 | 286 |
| 13   | Ghazouani, Lakhdar [39]. | Tunisia | 2010 | 58.1±12.0 | 56.7±14.1 | 418 | 406 |
| 14   | Humphries, S. E [40]. | England | 2001 | 56.7±3.6 | 56.0±3.4 | 162 | 2589 |
| 15   | Indumathi, B [41]. | India | 2019 | 56.00 ± 12.00 | – | 265 | 205 |
| 16   | Jabir, N. R [42]. | Saudi Arabia | 2017 | 60.6±8.85 | 47.7±5.06 | 90 | 89 |
| 17   | Jia, X. W [43]. | China | 2010 | – | – | 231 | 210 |
| 18   | Jun, M [44]. | China | 2017 | 63.5±13.6 | 64.2±14.1 | 860 | 862 |
| 19   | Li, L. [45]. | China | 2015 | – | – | 365 | 365 |
| 20   | Maitra, A [46]. | India | 2008 | 57.17 ± 9.22 | 45.53 ± 5.98 | 46 | 40 |
| 21   | Mao, L. [47]. | China | 2016 | 62.65 ± 9.72 | 56.82 ± 9.80 | 224 | 260 |
| 22   | Mastana, S [48]. | India | 2017 | 49.51±11.06 | 45.02±14.46 | 143 | 136 |
| 23   | Mitrokhin, V. [49]. | Russia | 2017 | 70.37±13.45 | 74.94±7.43 | 198 | 116 |
| 24   | Nauck, M [50]. | Germany | 2002 | 63.77±9.89 | 58.30±11.83 | 2575 | 729 |
| 25   | Ormer, W [51]. | Turkey | 2016 | 42±3.80 | 39 ± 7.8 | 340 | 310 |
| 26   | Phulukdaree, Alisa [52]. | India | 2013 | 37.5 | – | 41 | 61 |
| 27   | Rios, D. L S [53]. | Brazil | 2010 | – | – | 414 | 253 |
| 28   | Sarecka-Hujar, Beata [54]. | Poland | 2008 | 43.8±6.1 | 35.4±10.4 | 177 | 202 |
| 29   | Satti, H. S [55]. | Pakistan | 2013 | 46.4 ± 18.7 | 35.2 ± 17.4 | 36 | 52 |
| 30   | Sekuri, C [56]. | Turkey | 2007 | 46.3 ± 7.8 | 44.3 ±7.2 | 115 | 105 |
| 31   | Shabana, N. A [4]. | Pakistan | 2018 | 59.10 ± 12.64 | 56.0 ± 10.4 | 404 | 219 |
| 32   | Sun, G. Q [57]. | China | 2014 | 61.2 ± 8.5 | 56.4 ± 11.6 | 296 | 327 |
| 33   | Tong, Z. C [58]. | China | 2013 | 61.4±8.7 | 60.6±9.6 | 326 | 341 |
| 34   | Tütün, Ufuk [59]. | Turkey | 2006 | 29±3.4 | 31.1 ± 4.0 | 21 | 50 |
| 35   | Wang, K [60]. | China | 2015 | 65.4 ± 8.4 | 64.9 ± 8.2 | 402 | 402 |
| 36   | Yang, H. T [61]. | China | 2015 | – | – | 410 | 410 |
| 37   | Yao, H. M [17]. | China | 2016 | 62.64±8.43 | 61.43±7.85 | 275 | 296 |
| Name                      | GG case group | GG control group | OR (CI)          | CG case group | CG control group | OR (CI)          | CC case group | CC control group | OR (CI)          |
|---------------------------|---------------|------------------|------------------|---------------|------------------|------------------|---------------|------------------|------------------|
| Amorim, Fernanda Gobbi   | 29            | 41               | 0.493 (0.254–0.961) | 37            | 27               | 1.723 (0.885–3.352) | 6             | 3                | 2.061 (0.495–8.582) |
| Ansari, Wafa Munir       | 242           | 236              | 0.774 (0.545–1.100) | 85            | 71               | 1.122 (0.782–1.610) | 13            | 3                | 4.068 (1.148–14.414) |
| Babu, Baddela M. V. Srikanth | 134         | 135              | 0.570 (0.432–0.753) | 294           | 206              | 0.903 (0.708–1.153)  | 123           | 91               | 0.873 (0.645–1.182)  |
| Banerjee, Indranil       | 159           | 171              | 1.112 (0.723–1.710) | 43            | 57               | 0.791 (0.505–1.329)  | 8             | 4                | 2.257 (0.670–7.609)  |
| Basso, F.                | 161           | 375              | 0.934 (0.75–1.170)  | 259           | 549              | 1.103 (0.893–1.363)  | 78            | 185              | 0.927 (0.694–1.237)  |
| Bhanushali, A. A.        | 77            | 121              | 0.802 (0.433–1.488) | 20            | 25               | 1.250 (0.652–2.398)  | 3             | 4                | 1.129 (0.247–5.155)  |
| Chen, H.                 | 155           | 190              | 1.168 (0.874–1.560) | 218           | 133              | 4.665 (3.420–6.364)  | 56            | 27               | 3.135 (1.931–5.089)  |
| Elsaid, A.               | 23            | 55               | 0.433 (0.290–0.647) | 55            | 49               | 1.991 (1.194–3.320)  | 26            | 0                | 92.188 (5.545–1532.625) |
| Fan, W. H.               | 84            | 129              | 1.958 (0.048–48.619) | 0             | 1                | 0.511 (0.021–12.668) | –             | –                | –                |
| Galimudi, R. K.          | 72            | 113              | 0.433 (0.245–0.766) | 102           | 69               | 1.976 (1.322–2.955)  | 26            | 18               | 1.511 (0.800–2.854)  |
| Gao, Y. L.               | 183           | 224              | 0.551 (0.378–0.802) | 50            | 47               | 1.130 (0.729–1.751)  | 42            | 15               | 3.257 (1.761–6.024)  |
| Ghazouani, Lakhdar       | 298           | 297              | 0.911 (0.672–1.237) | 110           | 102              | 1.064 (0.779–1.455)  | 10            | 7                | 1.397 (0.527–3.706)  |
| Humphries, S. E.         | 40            | 827              | 0.699 (0.484–1.008) | 95            | 1263             | 1.489 (1.079–2.054) | 25           | 470              | 0.823 (0.531–1.275)  |
| Indumathi, B.            | 163           | 145              | 0.661 (0.448–0.976) | 99            | 57               | 1.549 (1.044–2.296)  | 3             | 3                | 0.771 (0.154–3.860)  |
| Jabir, N. R              | 62            | 63               | 0.914 (0.483–1.731) | 25            | 23               | 1.104 (0.569–2.139)  | 3             | 3                | 0.089 (0.194–5.034)  |
| Jun, M.                  | 450           | 503              | 0.783 (0.648–0.948) | 338           | 311              | 1.147 (0.944–1.34)   | 72            | 48               | 1.549 (1.062–2.262)  |
| Li, L.                   | 213           | 245              | 0.686 (0.508–0.928) | 113           | 105              | 1.110 (0.809–1.525)  | 39            | 15               | 2.791 (1.510–5.160)  |
| Maitra, A.               | 36            | 30               | 1.2 (0.441–3.267)   | 10            | 7                | 1.310 (0.447–3.838)  | 0             | 3                | 0.115 (0.006–2.301)  |
| Mao, L.                  | 142           | 193              | 0.601              | 45            | 45               | 1.201              | 37            | 22               | 2.140 (1.221–5.399)  |
Table 2  Odds ratio of studies that entered the meta-analysis stage (IL-6 -174 G>C and coronary and IL-6572 C>G and coronary artery disease) (Continued)

| Name            | CC  | Case | CG  | Control | OR  | GG  | Control |
|-----------------|-----|------|-----|---------|-----|-----|---------|
| Mastana, S.     | 105 | 91   | 32  | 39      | 1.366 (0.816–2.287) | 328 | 355 | 0.976 (0.828–1.150) | 3.752 |
| Mitrokhin, V.   | 62  | 32   | 100 | 58      | 1.197 (0.722–1.985) | 128 | 355 | 0.976 (0.828–1.150) | 36  | 26  | 0.769 (0.437–1.355) | 0.769 |
| Nauck, M.       | 838 | 230  | 1238| 355     | 1.047 (0.877–1.249) | 499 | 144 | 0.769 (0.437–1.355) | 499 | 144 | 0.976 (0.794–1.201) | 3.752 |
| Omer, W.        | 13  | 3    | 4.068 (1.148–14.414) | 11 | 19  | 0.811 (0.337–1.950) | 1   | 8   | 0.166 (0.020–1.378) | 0.717 |
| Phulukdaree, Alisa | 29  | 34   | 1.919 (0.827–4.451) | 126 | 86  | 1.159 (0.676–1.966) | 34  | 13  | 1.652 (0.854–3.194) | 3.752 |
| Rios, D. L. S.  | 254 | 151  | 1.072 (0.779–1.476) | 92 | 105 | 1.068–1.168 | 34  | 13  | 1.652 (0.854–3.194) | 3.752 |
| Shabana, N. A.  | 194 | 96   | 1.184 (0.850–1.647) | 133 | 90  | 0.703 (0.501–0.988) | 99  | 33  | 1.830 (1.185–2.824) | 0.717 |
| Sun, G. Q.      | 191 | 236  | 0.701 (0.500–0.985) | 61 | 63  | 1.088 (0.734–1.612) | 44  | 28  | 1.865 (1.128–3.082) | 0.717 |
| Tong, Z. C.     | 201 | 220  | 0.884 (0.646–1.212) | 87 | 98  | 0.903 (0.643–1.267) | 38  | 23  | 1.824 (1.061–3.136) | 0.717 |
| Tütün, Ufuk     | 11  | 35   | 0.471 (0.165–1.345) | 6 | 15  | 0.933 (0.303–2.870) | 4   | 0   | 25.971 (1.330–507.193) | 0.717 |
| Wang, K         | 153 | 182  | 0.743 (0.561–1.084) | 171 | 169 | 1.021 (0.771–1.350) | 51  | 78  | 1.657 (1.129–2.432) | 0.717 |
| Yang, H. T.     | 198 | 239  | 0.668 (0.507–0.880) | 163 | 146 | 1.193 (0.899–1.583) | 49  | 25  | 2.090 (1.264–3.456) | 0.717 |
| Yao, H. M.      | 256 | 282  | 0.669 (0.329–1.362) | 19 | 14  | 1.495 (0.734–3.043) | –   | –   | – | 0.717 |
| Basso, F.       | 1   | 2    | 1.113 (0.101–12.290) | 56 | 116  | 1.083 (0.773–1.519) | 425 | 959 | 0.905 (0.668–1.224) | 0.717 |
| Chen, H.        | 228 | 176  | 3.487 (2.563–4.743) | 158 | 131 | 2.192 (1.624–2.958) | 43  | 33  | 1.849 (1.146–2.985) | 0.717 |

IL-6572 C>G and coronary artery disease
the difference in the volume of case and control samples in the studied studies. The number of samples in each study is adjusted according to the objectives of that study and as reported in Table 1 among all studies are different.

### Table 2 Odds ration of studies that entered the meta-analysis stage (IL-6 -174 G>C and coronary and IL-6572 C>G and coronary artery disease) (Continued)

|      |         |       |     |     |       |     |     |
|------|---------|-------|-----|-----|-------|-----|-----|
| Fan, W. H. | 42     | 95  | 0.368 | 0.656 | 38   | 32  | 2.530 | 4.547 |
| Fragoso, J. M. | 23   | 36  | 0.516 | 0.899 | 146  | 103 | 1.479 | 2.086 |
| Gao, Y. L. | 114    | 129  | 0.862 | 1.204 | 134  | 135 | 1.063 | 1.481 |
| Humphries, S. E. | 0   | 9   | 0.836 | 14.23 | 19   | 225 | 1.396 | 2.96 |
| Jabir, N. R | 3     | 0   | 7.160 | 140.655 | 22   | 21  | 1.048 | 2.807 |
| Jia, X. W. | 79     | 88   | 0.721 | 1.060 | 130  | 107 | 1.239 | 1.803 |
| Jun, M. | 427    | 555  | 0.545 | 0.662 | 337  | 264 | 1.460 | 1.781 |
| Li, L. | 132    | 166  | 0.679 | 0.914 | 165  | 155 | 1.118 | 1.498 |
| Maitra, A. | 8     | 6   | 1.193 | 3.787 | 15   | 23  | 0.358 | 0.862 |
| Mao, L. | 81     | 106  | 0.823 | 1.189 | 110  | 127 | 1.010 | 1.445 |
| Mitrokhin, V. | 0   | 2   | 0.115 | 2.424 | 16   | 10  | 0.932 | 2.128 |
| Sun, G. Q. | 37    | 39  | 1.055 | 1.705 | 69   | 73  | 1.058 | 1.538 |
| Tong, Z. C. | 179  | 180 | 1.089 | 1.477 | 110  | 121 | 0.926 | 1.274 |
| Wang, K | 176    | 192  | 0.852 | 1.124 | 187  | 181 | 1.062 | 1.402 |

### Table 3 Heterogeneity and publication bias in the studied genotypes

| Genotype | I² | Egger’s test |
|----------|----|--------------|
| GG       | 59.1% | 0.740 |
| CG       | 79.2% | 0.231 |
| CC       | 70%  | 0.056 |

**Meta-analysis of genotype GG**

The total number of samples entered in the study was 11,463 and 12,316 for the case and control groups respectively. The odds ratio of GG genotype in patients with coronary artery disease based on meta-analysis of 35 studies was 0.8 (95% CI 0.72–0.89), which tends to reduce the risk of CAD by 0.2, meaning that people with this genotype are 20% less likely than others to tend coronary artery disease (Fig. 3). Figure 3 illustrates the odds ratio based on the model of random effects. The black small rectangle is the odds ratio, and the length of the line on which the square is located, is a representative of the 95% significance level for each study. The diamond sign represents the odds ratio for all studies.
Meta-analysis of genotype CG

The total number of samples entered in the study was 11,463 and 12,316 for the case and control groups respectively. The odds ratio of CG genotype in patients with coronary artery disease based on meta-analysis of 35 studies by 1.16 (95% CI: 1.02–1.32), which indicates the increasing effect of CG genotype with 0.16, meaning that people with this genotype are 16% more likely than others to have coronary artery disease (Fig. 4). Figure 4 illustrates the odds ratio based on the model of random effects. The black small rectangle is the odds ratio, and the length of the line on which the square is located, is a representative of the 95% significance level for each study. The diamond sign represents the odds ratio for all studies.

Meta-analysis of genotype CC

The total number of samples entered in the study was 11,104 and 11,890 for the case and control groups respectively. The odds ratio of CC genotype in patients with coronary artery disease based on meta-analysis of 33 studies was 1.48 (95% CI: 1.21–1.91), which indicates the increasing effect of CC genotype by 0.48, meaning that people with this genotype are 48% more likely than others to have coronary artery disease (Fig. 5). Figure 5 illustrates the odds ratio based on the model of random effects. The black small rectangle is the odds ratio, and the length of the line on which the square is located, is a representative of the 95% significance level for each study. The diamond sign represents the odds ratio for all studies.

Gene Interleukin-6 (IL-6) 572C>G

Investigation of heterogeneity and publication bias (GG, CG, CC genotypes)

The heterogeneity of the studies was investigated using I² test and based on this test, the heterogeneity in GG, CG and CC genotypes were calculated as I² = 59.6%, I² = 62.4%, and I² = 87.7% respectively. The results demonstrate a high level of heterogeneity among articles, and therefore the random effects model was used to amalgamate the results from these studies. The publication bias was calculated using the Egger’s test; the test did not find bias in any of the genotypes, since the results were not statistically significant (P > 0.05) (Table 4).

Meta-analysis of genotype GG

The total number of samples entered in the study was 4663 and 7801 for the case and control groups respectively. The odds ratio of GG genotype in patients with coronary artery disease based on meta-analysis of 16 studies was 1.27 (95% CI: 1.05–1.55), which indicates the
### Study name: Meta Analysis

**Fig. 4** The odds ratio of CG genotype in patients with coronary artery disease

### Study name: Meta Analysis

**Fig. 5** The odds ratio of CC genotype in patients with coronary artery disease
increasing effect of GG genotype by 0.27, meaning that people with this genotype are 27% more likely than others to have coronary artery disease (Fig. 6). Figure 6 illustrates the odds ratio based on the model of random effects. The black small rectangle is the odds ratio, and the length of the line on which the square is located, is a representative of the 95% significance level for each study. The diamond sign represents the odds ratio for all studies.

**Meta-analysis of genotype CG**

The total number of samples entered in the study was 4663 and 6615 for the case and control groups respectively. The odds ratio of CG genotype in patients with coronary artery disease based on meta-analysis of 16 studies was 1.21 (95% CI: 1.04–1.41), which indicates the increasing effect of CG genotype by 0.21, meaning that people with this genotype are 21% more likely than others to have coronary artery disease (Fig. 7). Figure 7 illustrates the odds ratio based on the model of random effects. The black small rectangle is the odds ratio, and the length of the line on which the square is located, is a representative of the 95% significance level for each study. The diamond sign represents the odds ratio for all studies.

**Meta-analysis of genotype CC**

The total number of samples entered in the study was 4165 and 7801 for the case and control groups respectively. The odds ratio of CC genotype in patients with coronary artery disease based on meta-analysis of 16 studies was 0.85 (95% CI: 0.61–1.18), which tends to reduce the risk of CAD by 0.15, meaning that people with this genotype are 15% less likely than others to tend coronary artery disease (Fig. 8). Figure 8 illustrates the odds ratio based on the model of random effects. The black small rectangle is the odds ratio, and the length of the line on which the square is located, is a representative of the 95% significance level for each study. The diamond sign represents the odds ratio for all studies.

**Discussion**

Cardiovascular disorders, including coronary artery disease, have a very complex etiology. However, the impact of environmental and genetic factors on the occurrence of these diseases has been verified. Factors influencing the incidence of this disease are divided into two categories: modifiable and unmodifiable [62, 63]. In other words, factors such as diabetes, smoking, obesity, blood pressure and stress are among the factors that can be corrected. Genetics, age and gender are considered as unmodifiable factors. Known genetic factors slightly increase the risk of coronary artery disease. However, genetic patterns that greatly increase the risk of CAD are still unknown [38, 64]. However, genetic susceptibility that exposes individuals to abnormal levels of atherosclerosis also intensified the risk of developing CAD [62–65].

**Table 4** Heterogeneity and publication bias in the studied genotypes

| Genotype | I² (%) | Egger’s test |
|----------|--------|--------------|
| GG       | 59.6%  | 0.135        |
| CG       | 62.4%  | 0.290        |
| CC       | 87.7%  | 0.821        |

**Fig. 6** The odds ratio of GG genotype in patients with coronary artery disease

**Fig. 7** The odds ratio of CG genotype in patients with coronary artery disease

**Fig. 8** The odds ratio of CC genotype in patients with coronary artery disease
The development of techniques in the field of biomolecules has made it possible to conduct comprehensive studies on polymorphisms. Examination of the polymorphism of cytokine genes, including interleukin-6, has shown that the production of these proteins varies from one person to another. It has also been shown that different pathways of interleukin-6 (IL-6) protein expression have specific biological roles in the development of CAD susceptibility [50].

In this study, the relationship between two different polymorphisms of the interleukin-6 (IL-6) gene was investigated by a systematic review and meta-analysis. After analyzing data related to interleukin-6 (IL-6) 174G>C polymorphism and its relationship to CAD, it was highlighted that CC genotype has a more increasing effect (with 48% higher likelihood) than other genotypes. The heterozygous genotype also increases the chances of developing CAD by 16%, whereas the GG genotype offers a 20% protective effect; in other words, the risk of developing CAD in carriers of this genotype is 20% lower than others. It has been observed that in this polymorphism, allele C acts as a risk factor for coronary artery disease.

---

**Fig. 7** The odds ratio of CG genotype in patients with coronary artery disease

**Fig. 8** The odds ratio of CC genotype in patients with coronary artery disease

---

| Study name | Odds ratio | 95% CI | p-Value |
|------------|------------|--------|---------|
| Basso, F.  | 1.083      | 0.773  | 1.519   | 0.465   | 0.642   |
| Chen, H.   | 2.192      | 1.624  | 2.768   | 5.128   | 0.000   |
| Fan, W. H. | 2.530      | 1.407  | 4.547   | 3.102   | 0.002   |
| Fragozo, J. M. | 1.479  | 1.049  | 2.086   | 2.232   | 0.026   |
| Gao, Y. L. | 1.063      | 0.763  | 1.481   | 0.361   | 0.719   |
| Humphries, S. E. | 1.396 | 0.849  | 2.296   | 1.314   | 0.189   |
| Jabir, N. R. | 1.048   | 0.528  | 2.090   | 0.133   | 0.894   |
| Jia, X. W. | 1.239      | 0.851  | 1.603   | 1.120   | 0.263   |
| Jun, M.    | 1.450      | 1.196  | 1.761   | 3.719   | 0.000   |
| Li, L.     | 1.118      | 0.834  | 1.498   | 0.746   | 0.456   |
| Malira, A. | 0.358      | 0.148  | 0.862   | -2.292  | 0.022   |
| Mao, L.    | 1.010      | 0.707  | 1.445   | 0.057   | 0.954   |
| Mitrokin, V. | 0.932   | 0.408  | 2.129   | -0.168  | 0.867   |
| Sun, G. Q. | 1.058      | 0.727  | 1.538   | 0.293   | 0.769   |
| Tong, Z. C. | 0.926   | 0.673  | 1.274   | -0.472  | 0.637   |
| Wang, K.   | 1.962      | 0.805  | 1.402   | 0.425   | 0.671   |
|            | 1.212      | 1.040  | 1.412   | 2.407   | 0.014   |

---

**Study name** | **Statistics for each study** | **Odds ratio and 95% CI**
|-----------------|-----------------------------|
| Basso, F.       | 1.113 0.101 12.299 0.067 0.531 |
| Chen, H.        | 3.487 2.563 4.743 7.964 0.000 |
| Fan, W. H.      | 0.368 0.207 0.656 3.391 0.001 |
| Fragozo, J. M.  | 0.956 0.297 0.889 2.338 0.019 |
| Gao, Y. L.      | 0.862 0.617 1.204 0.872 0.383 |
| Humphries, S. E.| 0.836 0.048 14.423 0.123 0.902 |
| Jabir, N. R.    | 7.160 0.364 140.655 1.296 0.195 |
| Jia, X. W.      | 0.721 0.490 1.000 1.164 0.096 |
| Jun, M.         | 0.545 0.450 0.662 6.150 0.000 |
| Li, L.          | 0.679 0.506 0.914 2.556 0.011 |
| Malira, A.      | 1.193 0.376 3.787 0.259 0.765 |
| Mao, L.         | 0.823 0.570 1.189 0.103 0.999 |
| Mitrokin, V.    | 0.115 0.005 2.424 1.390 0.165 |
| Sun, G. Q.      | 1.055 0.653 1.705 0.218 0.827 |
| Tong, Z. C.     | 1.089 0.603 1.787 0.549 0.583 |
| Wang, K.        | 0.852 0.645 1.224 1.132 0.269 |
|                 | 0.858 0.619 1.189 -0.921 0.357 |
artery disease. Moreover, by analyzing the information related to Interleukin-6 (IL-6) -572C>G polymorphism, it was found that CC genotype exerts its protective effect by 15% in this polymorphism, whereas CG and GG genotypes increase the risk of developing CAD by 21 and 27% respectively. In this polymorphism, allele G increases the risk of CAD and is considered as a risk factor [50–55].

A study by González-Castro et al. (2019) demonstrated that the Interleukin-6 (IL-6) 174 gene was associated with CAD, highlighting that the homozygous genotype and the heterogeneous genotype increased the risk of developing CAD by up to 50 and 10% respectively. According to this study, dominance will increase the risk of CAD by 23%. This gene also generally increases the risk of cardiovascular disease [66]. Zheng et al., (2012), after reviewing 27 studies with systematic review and meta-analysis, argued that there was no association between Interleukin-6 (IL-6) -174G>C polymorphism and an increased risk of Coronary Heart Disease (CHD) [67]. According to another meta-analysis conducted by Zhang et al. (2018), after reviewing 46 studies related to Interleukin-6 (IL-6) 174 G>C, it was stated that the GG genotype exerts a 19% protective effect. CG and CC genotypes also increase the risk of CAD by 5 and 35% respectively. In this study, the relationship between Interleukin-6 (IL-6) -572 and CAD was also measured. According to the analysis, the GG genotype has a protective effect and the CG and GG genotypes have an increasing effect. Nevertheless, the results of the analysis of CC and GG genotypes in the Interleukin-6 (IL-6) 572 gene in the study are different from the results of our analysis [68]. The study of Aker et al. (2009) also showed that in Interleukin-6 (IL-6)-174 polymorphism, CC genotype increased the risk of CAD more than CG and GG genotypes [69].

According to literature, factors such as inflammation and activation of immune cells play a role in the development of coronary artery syndrome [70]. That is to say, inflammation and atherosclerosis have a similar pathophysiological pathway [65].

It is possible that small changes in serum levels of inflammatory agents may be a factor in the clinical course of the disease [71] Inflammatory cytokines, such as interleukins, are involved in some CAD predisposing factors. These include LDL cholesterol, arterial blood pressure, and diastolic heart function. Existing research works show that high Interleukin-6 (IL-6) concentration is directly related to the development of CAD [72]. According to a study by Toutouzas, et al. (2017) various Interleukin-6 (IL-6) 174 G>C polymorphism genotypes are associated with serum Interleukin-6 (IL-6) levels. Moreover, according to the same research, the CC genotype of this polymorphism increases serum IL-6 levels more than other genotypes. In other words, the C allele in this polymorphism has an increasing effect on the
serum level of Interleukin-6 (IL-6), increasing the risk of CAD development, and by affecting the formation of coronary plaques, it increases the clinical symptoms in a multi-year course [71]. Moreover, another research work demonstrated that Interleukin-6 (IL-6) 174 polymorphism had no significant correlation with the serum IL-6 levels [73].

Plasma concentrations of IL-6 can reflect the severity of inflammation caused by fibrous plaques. Therefore, by monitoring the concentration of IL-6 in a person’s bloodstream, the risk of developing CAD can be measured [74]. Studies show that IL-6 is a biomarker with better sensitivity and characteristics than CRP for the diagnosis of cardiovascular disease [75]. A study by Lindmark et al. (2001) argue that IL-6 levels also play a role in mortality from heart disease, in other words, the higher the plasma levels of this substance, the higher the mortality rate (Fig. 9) [76].

As mentioned earlier, CAD lesions are caused by fibrous plaques surrounded by lipids. Early atherosclerotic plaques are composed of CRP that may be similar to monocytes over time. In other words, the expression of CRP and adhesion molecules can stimulate chemokines and co-activate endothelial cells with lipopolysaccharides. Adhesive molecules are known to mediate T cells that are involved in creating immune responses to inflammation [38, 77].

Existing research works demonstrate that Interleukin-6 (IL-6) gene polymorphisms affect plasma levels of hsCRP and fibrinogen (47). High levels of CRP are known to be a risk factor for development of CAD. Moreover, risks associated with other various factors such as obesity and high blood pressure are seen in these people [65]. One common approach is to measure serum concentrations of anti-inflammatory agents such as hsCRP and interleukin 6. Both substances are considered as a risk factor for development of heart disease, and assessment of their levels are commonly used to determine the risk of inflammation [78]. Klimushina et al. (2019) argued that women carrying the GL Interleukin-6 (IL-6) 174 polymorphism had higher serum hsCRP levels than the CC genotype [73]. A study by Champan et al. (2003) which was conducted in Australia found that CG and CC genotypes increased the probability of developing fibroid plaques in the Australian population by 1.39 and 2.22 times respectively [78].

Conclusions
This study demonstrated that there is an association between IL-6174 and IL-6572 genes and the occurrence of coronary artery disease. According to the analyses conducted in this work, the protective effect of GG genotype in IL-6174 gene and CC genotype in IL-6572 gene were illustrated. It was also stated that the CG and CC genotypes of the IL-6174 gene have an increasing effect on coronary artery disease. Furthermore, it was observed that CG and GG genotypes in the IL-6572 gene increase the probability of developing CAD. And in general, people with the CC genotype of the IL-6174 gene are more at risk of developing CAD than others. In future studies, we can compare the plasma levels of interleukin-6 with each polymorphism and the risk of developing CAD.

Limitations
One of the limitations of this study was the lack of access to the full text of a number of studies; moreover, articles which were in a language other than English or Persian were considered for this systematic review and meta-analysis.
References

1. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37(7):2322–45.

2. Li Y-Y, Wang H, Wu J-J, Kim HJ, Yang X-G, Geng H-Y, et al. ALDH2 gene G487A polymorphism and coronary artery disease: a meta-analysis including 564 participants. J Cell Mol Med. 2018;22(3):1666–74.

3. Shahana NA, Ashiq S, Ijaz A, Khalid F, Saadat IU, Khan K, et al. Genetic risk score (GRS) constructed from polymorphisms in the PON1, IL-6, ITGB3, and ALDH2 genes is associated with the risk of coronary artery disease in Pakistani subjects. Lipids Health Dis. 2018;17(1):224.

4. Kathiresan S, Srivastava D. Genetics of Human Cardiovascular Disease. Cell. 2012;148(6):1242–57.

5. Lelieveld J, Klingmüller K, Pozzer A, Pöschl U, Fnais M, Daiber A, et al. Pathogenesis of Atherosclerosis. J Am Coll Cardiol. 2006;47(8, 9):1786–92.

6. Falk E. Pathogenesis of Atherosclerosis. J Am Coll Cardiol. 2006;47(8, 9):1786–92.

7. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.

8. American Diabetes Association. Cardiovascular Disease and Risk Management. Diabetes Care. 2017;40(Supplement 1):S175.

9. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.

10. Li Y-Y, Wang H, Wu J-J, Kim HJ, Yang X-G, Geng H-Y, et al. ALDH2 gene G487A polymorphism and coronary artery disease: a meta-analysis including 564 participants. J Cell Mol Med. 2018;22(3):1666–74.

11. Maguire EM, Pearce SWA, Xiao Q. Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease. Vascul Pharmacol. 2019;112:54–71.

12. Falk E. Pathogenesis of Atherosclerosis. J Am Coll Cardiol. 2006;47(8, 9):1786–92.

13. Thysgesen K, Alpert JS, White HD, Jaffe AS, Appie AS, Galvani M, et al. Universal definition of myocardial infarction. Circulation. 2007;116(22):2634–53.

14. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.

15. American Diabetes Association. Cardiovascular Disease and Risk Management. Diabetes Care. 2017;40(Supplement 1):S175.

16. Fog Bentzon I, Otsuka F, Yamata R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114(12):1852–66.

17. Fan Y, Zhao X, Zhang S, Zhang C, Pang J, Zhou Y. IL-4 rs2432530 was associated with risk of coronary artery disease in a Chinese population. Int J Clin Exp Pathol. 2017;10(4):4764–71.

18. Baigaz A, Farazmanddar T, Salehi A, Manzari RS, Attar M, Shabahazi M. Association of interleukin-18 gene promoter polymorphisms with coronary artery disease in northern Iranian population. Meta Gene. 2018;16:1–7.

19. Abdolmaleki F, Hayat SMG, Bianconi V, Johnston TP, Sahebkar A. Association between interleukin-6 -572C>G and -597G/A polymorphisms and risk of coronary artery disease in a Chinese population. J Thromb Thrombolysis. 2009;27(1):88–94.

20. Princess CR103

21. Babu BMVS, Reddy BP, Priya WHS, Munshi A, Rani HS, Latha GS, et al. Cytokine gene polymorphisms in the susceptibility to acute coronary syndrome. Genet Test Mol Markers. 2012;16(3):359–66.

22. Baranierrie J, Pandey U, Hassan GM, Parihar R, Tripathi V, Ganie S. Association between interleukin-6 gene polymorphisms and coronary artery disease in an Indian population. J Thromb Thrombolysis. 2009;27(1):88–94.

23. Basso F, Lowe GD, Rumley A, McMahon AD, Humphries SE. Interleukin-6−174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol. 2002;22(4):599–604.

24. Bhanusali AA, Das BR. Promoter variants in interleukin-6 and tumor necrosis factor alpha and risk of coronary artery disease in a population from Western India. Indian J Hum Genet. 2013;19(4):430–6.

25. Chen H, Ding SF, Liu X, Wu Y, Wu YU. Association of Interleukin-6 Gene Polymorphism and Environments Interactions with Coronary Artery Disease in a Chinese Han Population. Clin Exp Hypertens. 2018;40(6):514–77.

26. Elaia A, Abdel-Aziz AF, Elmoogy R, Elwafee AM. Association of polymorphisms G−174C, C in IL-6 gene and G−1082A in IL-10 gene with traditional cardiovascular risk factors in patients with coronary artery disease. Indian J Biochem Biophys. 2014;51(4):282–92.

27. Fan WH, Liu DL, Xiao LM, Xie CJ, Sun SY, Zhang JC. Coronary heart disease and chronic periodontitis: Is polymorphism of interleukin-6 gene the common risk factor in a Chinese population? Oral Dis. 2011;17(3):270–6.

28. Galimudi RK, Spurthi MK, Padala C, Kumar KG, Mudigonda S, Reddy SG, et al. Interleukin-6 (−174G/C) variant and its circulating levels in coronary artery disease patients and their first degree relatives. Inflammation. 2014;37(2):314–21.

29. Gao YL, Jiang W, Yan QN, Li ZL. Association between IL-6-174G/C and -572G/C polymorphisms and risk of coronary artery disease in a Chinese population. Int J Clin Exp Pathol. 2016;9(1):282–7.

30. Ghazouani L, Khalifa SBH, Abboud N, Hamda KB, Khalifallah AB, Ibrahim N, et al. TNF−α−308G>A and IL−6−174G>C polymorphisms in Tunisian patients with coronary artery disease. Clin Biochem. 2010;43(13-14):1085–9.

31. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 (IL-6) cytokine gene polymorphisms -174 G/C and -572 G/C are associated with risk of coronary artery disease and systolic blood pressure in healthy men. Eur Heart J. 2001;22(24):2243–52.

32. Indumathi B, Katkam SK, Krishna LSR, Kutrala VK. Dual Effect of IL-6−174G/C Polymorphism and Promoter Methylation in the Risk of Coronary Artery Disease Among South Indians. Indian J Clin Biochem. 2019;34(2):1870–7.

33. Jabar NR, Firoz CK, Kamal MA, Damanhour GA, Alama MN, Alzahrani AS, et al. Assessment of genetic diversity in IL-6 and RANTES promoters and their level in Saudi coronary artery disease patients. J Clin Lab Anal. 2017;31(5):e22092.

34. Ja JW, Tian YP, Wang Y, Deng XX, Dong ZN, Scafe N, et al. Association between the interleukin-6 gene-572G/C and-597G/A polymorphisms and coronary heart disease in the Han Chinese. Med Sci Monit. 2010;16(3):CR103–CR8.
44. Jun M, Xue-Qiang G, Jia L, Yang-Jing X, Cheng Z, Ge J. Interactions between vitamin D receptor (VDR) gene and interleukin-6 gene and environmental factors on coronary heart disease risk in a Chinese Han population. Oncotarget. 2017;8(45):78419–28.

45. Li L, Li F, Zhang LH, Jiao LG, Liu HP, Wang T. IL-6-174G/C and IL-6-572G/C polymorphisms are associated with increased risk of coronary artery disease. Genet Mol Res. 2015;14(3):8451–7.

46. Maita A, Shanker J, Dash D, John S, Sannappra PR, Rao VS, et al. Polymorphisms in the IL6 gene in Asian Indian families with premature coronary artery disease - The Indian Atherosclerosis Research Study. Thromb Haemost. 2008;99(5):944–50.

47. Mao L, Geng GY, Han WJ, Zhao MH, Wu L, Liu HL. Interleukin-6 (IL-6) -174G/C genotypic polymorphism contribution to the risk of coronary artery disease in a Chinese population. Genet Mol Res. 2016;15(2):15–43.

48. Mastana S, Prakash S, Akam EC, Kirby M, Lindley MR, Sinha N, et al. Genetic association of pro-inflammatory cytokine gene polymorphisms with coronary artery disease (CAD) in a North Indian population. Gene. 2017;628: 301–7.

49. Mitrovic V, Nikitin A, Brovkina O, Khodyrev D, Zotov A, Vachrushev N, et al. Association between interleukin-6/-6G and polymorphisms and coronary artery disease in Russian population: Influence of interleukin-6/-112G polymorphism on inflammatory markers. Journal of Inflammation Research. 2017;10:151–60.

50. Nauck M, Winkelmann BR, Hoffmann MM, Böhm BO, Welander H, März W. The interleukin-6 G/-174 C promoter polymorphism in the LURIC cohort: No association with plasma interleukin-6, coronary artery disease, and myocardial infarction. J Mol Med. 2002;80(8):507–13.

51. Omer W, Naveda AK, Khan OJ, Khan DA. Role of Cytokine Gene Score in the Risk Prediction of Coronary Artery Disease. Genet Test Mol Biomarkers. 2016;20(11):880–91.

52. Phulukdaree A, Khan S, Ramkaran P, Govender R, Moodley D, Chuturgoon AA. The Interleukin-6 -174 G/C Polymorphism Is Associated with Increased Risk of Coronary Artery Disease in Young South African Indian Men. Metab Syndr Relat Disord. 2013;11(3):205–9.

53. Rios DLS, Cerqueira CCS, Bonfim-Silva R, Araújo LJ, Pereira JF, Gadelha SR, et al. Interleukin-1 beta and interleukin-6 gene polymorphism associations with angiographically assessed coronary artery disease in Brazilians. Cytokine. 2010;50(3):292–6.

54. Sarecka-Hujar B, Zal I, Krause J. Carrier-state of two or three polymorphic variants of MTHFR, IL-4 and IACAM1 genes increases the risk of coronary artery disease. Kardiol Pol. 2008;66(12):1269–77.

55. Satti HS, Hussain S, Javed Q. Association of Interleukin-6 Gene Promoter Polymorphism with Coronary Artery Disease in Pakistani Families. The Scientific World Journal. 2013;2013:58365. https://doi.org/10.1155/2013/58365.

56. Sekulc C, Cam FS, Sagan A, Ercan E, Tengiz I, Alkoglu E, et al. No association of interleukin-6 gene polymorphism (+174 G/C) with premature coronary artery disease in a Turkish cohort. Coron Dis. 2007;18(3):333–7.

57. Sun GQ, Wu GD, Meng Y, Du B, Li YB. IL-6 gene promoter polymorphisms and risk of coronary artery disease in a Chinese population. Genet Mol Res. 2014;13(3):7718–24.

58. Tong ZC, Li Q, Zhang JJ, Wei Y, Miao GB, Yang XC. Association between interleukin 6 and interleukin 16 gene polymorphisms and coronary heart disease risk in a Chinese population. J Int Med Res. 2013;41(4):1049–56.

59. Tütün U, Aksüyek A, Uzun AT, Mıroğlu M, Çöçekpoglu F, Özsk K, et al. Gene polymorphisms in patients below 35 years of age who underwent coronary artery bypass surgery. Coron Artery Dis. 2006;17(1):35–9.

60. Wang K, Dong FS, Zhang HF, Li ZJ, Yang XM, Liu H. Role of interleukin-6 gene polymorphisms in the risk of coronary artery disease. Genet Mol Res. 2015;14(2):3177–83.

61. Yang HT, Wang SL, Yan LJ, Qian P, Duan HY. Association of interleukin gene polymorphisms with coronary artery disease. Genetics and Molecular Research. 2015;14(4):12489–96.

62. Yao HM, Jia YP, Lv JY. Interleukin-6 polymorphisms and risk of coronary artery diseases in a Chinese population: A case-control study. Pakistan J Sci. 2016;33(186):880–5.

63. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature. 2010;464(7287):409–12.

64. Bachchiea BC, Bachchiea AB, Usnayo MG, Bedirian R, Singh G, GedRC. Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J Am Heart Assoc. 2017;6(3):005038.

65. González-Castro TB, Hernández-Díaz Y, Pérez-Hernández N, Tovilla-Zárate CA, Juarez-Rojro J, López-Navarrete ML, et al. Interleukin 6 (rs1800795) gene polymorphism is associated with cardiovascular diseases: a meta-analysis of 74 studies with 85,229 subjects. EXCLI J. 2019;18:331–55.

66. Zheng GH, Chen HY, Xiong SQ. Polymorphisms of -174G>C and -572G>C in the interleukin 6 (IL-6) gene and coronary heart disease risk: a meta-analysis of 27 research studies. PLoS One. 2012;7(4):e34839.

67. Zhang H, Liu C, Zhao B, Zhou X. An Evidence-Based Meta-Analysis on the Rules of Functional Interleukin-6 Polymorphisms in Coronary Artery Disease. J Interferon Cytokine Res. 2018;38(9):370–7.

68. Aker S, Bantis C, Reis P, Kuhn NH, Schwanitz C, Grabensee B, et al. Influence of interleukin-6 G/-174C gene polymorphism on coronary artery disease, cardiovascular complications and mortality in dialysis patients. Nephrol Dial Transplant. 2009;24(9):2847–51.

69. Ikeda U. Inflammation and Coronary Artery Disease. Curr Vasc Pharmacol. 2003;1:65–70.

70. Toutouzas K, Klettas D, Anousakis-Machoxicristou N, Melidis K, Azilazian Z, Asimomiti M, et al. The -174 G/C polymorphism of interleukin-6 gene polymorphism is associated with angiographic progression of coronary artery disease over a 4-year period. Hellenic J Cardiol. 2017;58(1):80–6.

71. Eras S, Tejeira-Fernández E, Shamagian LG, Fernandez AL, Vazquez-Boquete A, González-Juanatey JR. Extension of coronary artery disease is associated with increased IL-6 and decreased adiponectin gene expression in epicardial adipose tissue. Cytokine. 2008;43(2):174–80.

72. Klimushina MV, Gumanova NG, Kusenko VA, Dvashuk MG, Smetnev SA, Kiseleva AV, et al. Association of common polymorphisms in IL-6 and IL6ST genes with levels of inflammatory markers and coronary stenosis. Meta Gene. 2019;21:100593.

73. Ikeda U, Ito T, Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol. 2002;24(11):701–4.

74. Lubrano V, Cocci F, Battaglia D, Papa A, Marconcin P, Zucchini GC. Usefulness of high-sensitivity IL-6 measurement for clinical characterization of patients with coronary artery disease. J Clin Lab Anal. 2005;19(3):110–4.

75. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286(17): 2107–13.

76. Ren G, Roberts AI, Shi Y. Adhesion molecules: key players in Mesenchymal stem cell-mediated immunosuppression. Cell adhesion & migration. 2011; 5(1):20–2.

77. Antoniades C, Antonopoulos AS, Deanfield J. Imaging residual inflammatory cardiovascular risk. Eur Heart J. 2000;21(16):748–58.

78. Chapman CML, Bellby JP, Humphries SE, Palmer LJ, Thompson PL, Hung J. Association of an allelic variant of interleukin-6 with subclinical carotid atherosclerosis in an Australian community population. Eur Heart J. 2003;24(16):1494–9.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.